Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
about
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.The role of the JAK/STAT signal pathway in rheumatoid arthritis.
P2860
Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Peficitinib, a JAK Inhibitor, ...... uate Response to Methotrexate.
@en
type
label
Peficitinib, a JAK Inhibitor, ...... uate Response to Methotrexate.
@en
prefLabel
Peficitinib, a JAK Inhibitor, ...... uate Response to Methotrexate.
@en
P2093
P2860
P356
P1476
Peficitinib, a JAK Inhibitor, ...... uate Response to Methotrexate.
@en
P2093
A J Kivitz
A Zubrzycka-Sienkiewicz
M C Genovese
S R Gutierrez-Ureña
P2860
P304
P356
10.1002/ART.39955
P577
2016-10-16T00:00:00Z